Indivior PLC (INDV)

Currency in USD
38.82
+0.15(+0.39%)
Closed·
38.820.00(0.00%)
·
INDV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
38.0838.91
52 wk Range
21.8342.81
Key Statistics
Prev. Close
38.67
Open
38.83
Day's Range
38.08-38.91
52 wk Range
21.83-42.81
Volume
1.69M
Average Volume (3m)
1.98M
1-Year Change
76.4545%
Book Value / Share
-1.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INDV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
49.00
Upside
+26.22%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Indivior PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 49.00
(+26.22% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Buy43.00+10.77%46.00MaintainAug 05, 2026
Barclays
Buy46.00+18.50%-New CoverageJun 18, 2026
Jefferies
Buy50.00+28.80%45.00MaintainApr 30, 2026
H.C. Wainwright
Buy48.00+23.65%35.00MaintainJan 12, 2026
Craig-Hallum
Buy50.00+28.80%41.00MaintainJan 09, 2026

Indivior PLC Earnings Call Summary for Q2/2026

  • Supernus and Indivior beat Q2 2026 estimates with EPS of $1.15 vs. $0.74 forecast and revenue of $343M vs. $284.9M, up 55.4% and 20.4% respectively.
  • Companies announced all-stock merger creating CNS-focused drugmaker with $2.2B annual revenue, $888M adjusted EBITDA, and $125M expected cost synergies.
  • Combined entity to maintain four sales forces across ADHD, Parkinson's, women's health, and addiction; merger expected to close Q4 2026 pending approvals.
  • SUBLOCADE holds 76% share of long-acting injectable OUD market with record patient starts; Qelbree cited as fastest-growing ADHD brand driving momentum.
  • Pro forma company shows 41% adjusted EBITDA margin with $878M net debt; Indivior shares down 1.22% to $39.52 despite strong results and strategic rationale.
Last Updated: 2026-08-03, 09:40 a/m
Read Full Transcript

Earnings

Latest Release
Aug 03, 2026
EPS / Forecast
1.15 / 0.74
Revenue / Forecast
343M / 284.9M
EPS Revisions
Last 90 days

INDV Income Statement

Compare INDV to Peers and Sector

Metrics to compare
INDV
Peers
Sector
Relationship
P/E Ratio
12.9x21.4x−0.4x
PEG Ratio
0.060.060.00
Price/Book
−22.0x2.5x2.6x
Price / LTM Sales
3.4x5.0x3.0x
Upside (Analyst Target)
28.8%23.1%48.7%
Fair Value Upside
Unlock19.7%5.6%Unlock

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Employees
833

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
55.03M46.63%2.14B
Other Institutional Investors
93.07M53.37%3.61B
Public Companies & Retail Investors
0.000.00%0.00
Total
148.1M100.00%5.75B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.15.71%18,542,220719,809
Vanguard Portfolio Management, LLC6.69%7,891,819306,360

People Also Watch

18.410
ERAS
+0.77%
136.89
ECG
-1.89%
97.10
TIGO
-6.91%
59.90
KGS
+5.35%

FAQ

What Is the Indivior (INDV) Stock Price Today?

The Indivior stock price today is 38.82 USD.

What Stock Exchange Does Indivior Trade On?

Indivior is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Indivior?

The stock symbol for Indivior is "INDV."

What Is the Indivior Market Cap?

As of today, Indivior market cap is 4.56B USD.

What Is Indivior's Earnings Per Share (TTM)?

The Indivior EPS (TTM) is 2.77.

When Is the Next Indivior Earnings Date?

Indivior will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is INDV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Indivior Stock Split?

Indivior has split 0 times.

How Many Employees Does Indivior Have?

Indivior has 833 employees.

What is the current trading status of Indivior (INDV)?

As of Aug 08, 2026, Indivior (INDV) is trading at a price of 38.82 USD, with a previous close of 38.67 USD. The stock has fluctuated within a day range of 38.08 USD to 38.91 USD, while its 52-week range spans from 21.83 USD to 42.81 USD.

What Is Indivior (INDV) Price Target According to Analysts?

The average 12-month price target for Indivior is 49.00 USD, with a high estimate of 53 USD and a low estimate of 43 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +26.22% Upside potential.

What Is the INDV Premarket Price?

INDV's last pre-market stock price is 37.75 USD. The pre-market share volume is 1,220.00, and the stock has decreased by -0.92, or -2.38%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.